Cytokine-based therapies for Crohn's disease--new paradigms.
about
Association Between Inflammatory Bowel Disease and Vitamin D DeficiencyProfile of certolizumab and its potential in the treatment of psoriatic arthritisNew insights into the dichotomous role of innate cytokines in gut homeostasis and inflammationThe flavonoid luteolin worsens chemical-induced colitis in NF-kappaB(EGFP) transgenic mice through blockade of NF-kappaB-dependent protective moleculesMycophenolate Mofetil Modulates Differentiation of Th1/Th2 and the Secretion of Cytokines in an Active Crohn's Disease Mouse ModelProbiotic bacteria regulate intestinal epithelial permeability in experimental ileitis by a TNF-dependent mechanismEpithelial-derived IL-33 and its receptor ST2 are dysregulated in ulcerative colitis and in experimental Th1/Th2 driven enteritisRole of interleukin 6 in a murine model of Crohn's ileitis: are cytokine/anticytokine strategies the future for IBD therapies?Oxidative stress induced inflammation initiates functional decline of tear productionAssociations between genetic polymorphisms in IL-33, IL1R1 and risk for inflammatory bowel disease.New biologics in the management of Crohn's disease: focus on certolizumab pegol.Delving into disability in Crohn's disease: dysregulation of molecular pathways may explain skeletal muscle loss in Crohn's disease.Certolizumab pegol for the treatment of Crohn's disease.Enteral nutrition in the management of Crohn's disease.Immunopathogenesis of Crohn's disease.Potential role for immunomodulatory therapy in atherosclerotic plaque stabilisation.Opposing Functions of Classic and Novel IL-1 Family Members in Gut Health and Disease.Downregulation of sodium transporters and NHERF proteins in IBD patients and mouse colitis models: potential contributors to IBD-associated diarrheaT-cell-directed therapies in inflammatory bowel diseases.Recent advances in cytokines: therapeutic implications for inflammatory bowel diseases.Mitochondrial reactive oxygen species drive proinflammatory cytokine production.The dual role of nod-like receptors in mucosal innate immunity and chronic intestinal inflammation.Metabolic inflammation in inflammatory bowel disease: crosstalk between adipose tissue and bowel.Optimal vitamin D levels in Crohn's disease: a review.Curcumin and inflammatory bowel disease: potential and limits of innovative treatments.Role of epithelial ion transports in inflammatory bowel disease.Tumor necrosis factor-α represses the expression of NHE2 through NF-κB activation in intestinal epithelial cell model, C2BBe1.IFN-gamma and TNF-alpha regulate human NHE3 gene expression by modulating the Sp family transcription factors in human intestinal epithelial cell line C2BBe1.Functional defects in NOD2 signaling in experimental and human Crohn disease.Probiotics and ileitis: could augmentation of TNF/NFκB activity be the answer?QuantiFERON TB gold testing for tuberculosis screening in an inflammatory bowel disease cohort in the United States.The opioid antagonist naltrexone improves murine inflammatory bowel disease.Annonaceae: Breaking the Wall of Inflammation.Methyl jasmonate: a phytohormone with potential for the treatment of inflammatory bowel diseases.High prevalence of celiac disease among patients affected by Crohn's disease.
P2860
Q22242722-2C4084B7-975A-4A6B-9AFA-84954C984A3BQ22305856-EC714D90-7280-48F9-98A3-F7E15ECFFAB0Q26823773-36A3A8BD-9348-451C-8CB3-E007566CB294Q28469238-1BA79DE1-8BC4-4B3E-B651-1E768CAAA844Q30386671-3DC5BF62-1B3E-4FF5-9772-3C11993A73BDQ30425823-AC176547-7A8D-4B66-92AE-5175CA43029BQ30434426-F825A4E6-CC2D-4E93-8059-0C6606938C4AQ30438775-50803568-CDD5-4E1E-B8E2-720142048FD1Q34446876-AD855FCF-01A0-472F-B678-14DEDA07DA10Q34698326-DDC6024E-48C0-4D88-A973-51DC6B2D6165Q35026264-6CA1B885-86A9-4791-9857-DD1CBE8B8EC0Q35065914-011A6EBD-A7E5-4718-B3D4-0E7BC0A351B1Q35276666-F2F29FB9-FE5F-40ED-A618-68D588873ACEQ36175753-0E01EF17-577A-4006-9DF1-5FA0C01FDFDBQ36175758-33125E0B-5C9F-4929-8181-25D25CF045B9Q36283698-7CFE1B26-29D8-4A4C-89F2-DEF7C4240552Q36994761-92626043-4FD8-4023-9D28-3090D7B3BA3AQ37064596-611F78C2-91D3-4785-A7DF-9B18BD11F2A6Q37720783-E36E452B-4D29-4D42-87C0-C6946578A6A7Q37847059-FC57CEA2-7987-40B2-B610-83C736841FC5Q37847792-8A4BFECF-BA5A-4137-A3E9-6010DBE41F13Q38234947-2C44E1CC-2A51-4253-A025-95985E83C72FQ38253468-7EC3253F-6345-4F8B-AD81-E18786447450Q38286526-98B9B81F-100F-4706-B302-A50ACE9E21AEQ38292885-01E7CF06-37F5-4225-B9F2-6CB42B3E9BABQ38690199-A78D2A6A-9899-4365-8FB1-833867B8234FQ39665808-437586EA-B8D2-448E-87D2-4BD4CE6CE13CQ40270359-6C37D182-34C2-47DC-8C29-3002B5739406Q42018048-B318672A-F920-4E11-BD2B-61DF52D0F3D8Q42234301-7BF7EEC1-438B-437B-8FF3-E23506D26C2DQ43663890-6F088518-267E-401E-94C6-A926434C0A09Q44339195-10A406B9-0F96-437B-BE4A-1C9441E9FF3EQ46268493-32F9EAC6-7103-4B78-BE44-25C29E2E8F29Q46274377-134FC981-0014-4C93-BDC3-BFB3F1E4C3DCQ46562246-FF3F3EE3-1869-416F-A500-04C829A7F87E
P2860
Cytokine-based therapies for Crohn's disease--new paradigms.
description
2004 nî lūn-bûn
@nan
2004 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Cytokine-based therapies for Crohn's disease--new paradigms.
@ast
Cytokine-based therapies for Crohn's disease--new paradigms.
@en
type
label
Cytokine-based therapies for Crohn's disease--new paradigms.
@ast
Cytokine-based therapies for Crohn's disease--new paradigms.
@en
prefLabel
Cytokine-based therapies for Crohn's disease--new paradigms.
@ast
Cytokine-based therapies for Crohn's disease--new paradigms.
@en
P356
P1476
Cytokine-based therapies for Crohn's disease--new paradigms.
@en
P2093
Fabio Cominelli
P304
P356
10.1056/NEJMP048253
P407
P577
2004-11-01T00:00:00Z